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 Abstract  
Objectives:  
Extra-criteria manifestations of antiphospholipid syndrome (APS) 
might impact on prognosis and morbidity of the disease. In this study, 
we aimed to evaluate a population of patients with primary APS(PAPS) 
whether the extra-criteria manifestations were more frequently found 
in subjects with higher adjusted Global APS Score (aGAPSS)  values 
when compared to patients with thrombotic and/or obstetric 
APS(“criteria” manifestations) only. 
Methods:  
Clinical records were analyzed to retrieve extra-criteria manifestation 
of APS, cardiovascular risk factors and antiphospholipid antibodies 
profile. The aGAPSS was calculated by adding the points, as follows: 3 
for hyperlipidaemia, 1 for arterial hypertension, 5 for anticardiolipin 
antibodies IgG/IgM, 4 for anti-b2 glycoprotein I IgG/IgM and 4 for 
lupus anticoagulant. 
Results:  
This retrospective multicenter study included 89 consecutive PAPS 
[mean age 43.1(S.D.±12.9), female 67%, 52% arterial and 65% 
venous]. Twenty-seven patients (30.3%) had a history of livedo, 
19(21.3%) had a history of confirmed thrombocytopenia,3(3.4%) had 
biopsy-proven antiphospholipid antibodies (aPL)-related nephropathy 
and 3(3.4%) had a history of valvulopathy. Patients with extra-criteria 
manifestations presented a mean aGAPSS significantly higher [mean 
10.30(S.D.±3.57,range 4-17) vs mean 8.16(S.D.±3.52;range 4-
16,p=0.005). When comparing patients with and without extra-criteria 
manifestations, the first group had significantly higher incidence of 
anti-ß2GPI antibodies positivity (59% and 33%, respectively, 
p=0.015), double aPL positivities (53% and 31%, respectively, 
p=0.034), cerebrovascular events history(52% and24%, respectively, 
p=0.007) and arterial hypertension (52% and 24%, respectively, 
p=0.007).  
Conclusions:  
Our results suggest that patients with higher  aGAPSS, might be at 
higher risk for developing extra-criteria manifestations of APS and 
should therefore undergo a thorough laboratory and instrumental 
evaluation.  
  
1.1 Introduction  
The antiphospholipid syndrome (APS) is characterized by 
antiphospholipid antibodies (aPL) associated with thrombosis (arterial 
and/or venous) and/or pregnancy morbidity. The current Sydney 
classification criteria [1] do not consider a range of non-thrombotic 
clinical manifestations that are frequently observed in association with 
the presence of aPL, the so-called extra-criteria manifestations [2]. 
Although extra-criteria manifestations, such as thrombocytopenia, 
livedo reticularis, aPL related-nephropathy, cardiac valve disease, 
cognitive dysfunction and skin ulcers are relatively common, their 
accurate prevalence and associated thrombotic risk are unknown [3].  
Furthermore, despite the diagnostic value of these extra-criteria 
manifestations has yet to be determined,  they might be highly relevant 
and reveal correlations with prognosis or morbidity [4].  
In fact, patients with APS still suffer for a significant burden of 
morbidity and mortality regardless a proper management with the 
current therapeutic tools; thus, it is imperative to increase the efforts 
in determining optimal prognostic markers, risk assessments 
measures and therapies to prevent complications.  
Recently, the Global APS Score (GAPSS) and the adjusted GAPSS 
(aGAPSS), a simplified version of the same score, were designed to 
evaluate the risk of patients to develop any clinical manifestation of 
APS [5–8]. These scores are important to predict which patients are at 
higher risk and that consequently will need closer follow-up and 
eventually specific treatment. It is debated whether patients with non-
criteria manifestations are at a higher recurrence risk [4].  
The purpose of this study was to evaluate in a population of patients 
with primary APS (PAPS). whether the extra-criteria manifestations 
were more frequently found in subjects with higher aGAPSS values 
when compared to patients with thrombotic and/or obstetric APS 
(“criteria” manifestations) only. 
 
2.1 Patients and methods:   
2.2 Patients 
This retrospective multicenter study included 89 consecutive primary 
APS patients who attended the Hospital das Clinicas, Sao Paulo, Brazil 
and S. Giovanni Bosco Hospital, Turin, Italy. Inclusion criteria included 
the persistent aPL positivity and the fulfillment of the Sydney criteria 
for APS [1].  
Both centers are tertiary referral hospitals and are responsible for the 
management of severe APS patients. 
 2.3 Extra-criteria manifestations of APS  
Medical records were retrospectively checked for extra-manifestations 
of APS. Livedo reticularis and racemosa were assessed by physical 
examination as per standard of care of centers. Thrombocytopenia was 
defined as platelets level <100,000 mm3 and confirmed with at least 
two examinations with a complete blood count and evaluation of the 
peripheral blood smear. aPL-related nephropathy was assessed with 
kidney biopsy [9] and valvulopathy was confirmed with 
echocardiography [10].  
2.4 Autoantibody detection 
The aPL profile included anticardiolpin antibodies (aCL), lupus 
anticoagulant (LA) and anti-ß2 glycoprotein I (anti-ß2GPI) antibodies. 
Plasma samples were tested for the presence of LA according to the 
recommended criteria from the International Society on Thrombosis 
and Haemostasis (ISTH) Subcommittee on Lupus 
Anticoagulant/Phospholipid-Dependent Antibodies [11,12]. The aCL and 
anti-ß2GPI were detected by ELISA as described previously [13].  
2.5 Cardiovascular risk factors assessment 
Cardiovascular risk factors (including hypertension, dyslipidemia, 
diabetes, hormone replacement therapy and smoking) were assessed 
following the National Institute for Health and Care Excellence (NICE) 
guidelines [16]. In detail, enrolled patients underwent a physical 
examination, blood pressure determination and phlebotomy for 
vascular risk factors. Arterial hypertension was defined as an 
appropriately sized cut-off (140/90 mmHg or higher)[15], high blood 
pressure on at least two occasions or use of oral antihypertensive 
medications. Serum total and high-density lipoprotein (HDL) 
cholesterol levels were determined with standardized enzymic 
methods and interpreted according to current cut-off values [15]. 
2.6 Adjusted GAPSS calculation 
The cumulative aGAPSS was calculated for each patient as previously 
reported by adding together all points corresponding to the risk 
factors [5]. After its first description, GAPSS was prospectively 
validated [7] and applied in a cohort of patients with PAPS [8]. To 
increase the generalizability of the findings, in this study we applied an 
adjusted version of GAPSS (aGAPSS). This comprises only aPL testing 
included in the current classification criteria for APS (excluding aPS-
PT, not routinely available in all the laboratories). Data are presented 
as aGAPSS.The aGAPSS was calculated by adding the points 
corresponding to the risk factors, based on a linear transformation 
derived from the ß regression coefficient as follows: 3 for 
hyperlipidaemia, 1 for arterial hypertension, 5 for aCLIgG/IgM, 4 for 
anti-b2 glycoprotein I IgG/IgM and 4 for LA. 
2.8 Statistical analysis 
Categorical variables are presented as number (%) and continuous 
variables are presented as mean (S.D.). The significance of baseline 
differences was determined by the chi-squared test, Fisher’s exact test 
or the unpaired t-test, as appropriate. A two-sided P-value <0.05 was 
statistically significant. All statistical analyses were performed using 
SPSS version 19.0 (IBM, Armonk, NY, USA).  
3.1 Results:  
A total of 89 consecutive PAPS patients [mean age 43.1 (S.D.±12.9), 
female 67%] were included in the analysis.  Fourty-six patients had at 
least one episode of arterial thrombosis (51.7%) and 58 (65.2%) had 
at least one episode of venous thrombosis. Demographic, clinical and 
laboratory characteristics are summarized in Table 1.  
Patients Characteristics  All (89) % 
Female sex 67 75,2 
Age, mean (S.D.), years 43,1 (12,9) 
 
Venous thrombosis, n 58 65,2 
Arterial thrombosis, n 46 51,7 
Stroke, n  34 38,2 
Pregnance Morbidity 34 38,2 
Arterial Hypertension, n 24 29,9 
Hyperlipidemia, n 20 22,5 
Smoking, n  14 15,7 
Diabetes, n  7 7,8 
LA, n 73 82 
aCL IgG/M, n  56 62,9 
Anti-Beta2GPI IgG/IgM, n 41 46,1 
Double aPL positive 37 41,6 
Triple aPL positive 22 24,7 
aGAPSS, mean (S.D)  9,15 (3,7)  
Extra Criteria Manifestations   
Livedo, n  27 30,3 
Thrombocytopenia, n 19 21,3 
Valvulopathy, n  3 3,4 
Biopsy proven APS Nephropaty, n  3 3,4 
Table 1. Demographic, clinical and laboratory characteristics of the cohort 
aPL= Antiphospholipid antibodies; S.D. = standard deviation; aGAPSS = adjusted global antiphospholipid 
score  
 
When considering the extra-manifestation of APS, 27 patients (30.3%) 
had a history of livedo, of those 21 patients had livedoreticularisand six 
livedoracemosa. Nineteen patients (21.3%) had a history of confirmed 
thrombocytopenia(range 30,000/µl-100,000/µl), three patients 
(3.4%) had biopsy-proven aPL-related nephropathy and three patients 
(3.4%) had a history of valvulopathy. Table 2 summarizes the 
characteristics of patients between groups. 
 
 
 
 
Livedo  
(27) 
Thrombocytopenia 
(19) 
No extra-criteria 
manifestation 
 (45) 
Age (mean, SD) 48 ±11.4 41.9 ±14.2 33 ±12.9 
Sex (females) 23 (85.2%)  12 (63.2%)  33 (73.3%) 
Hyperlipidemia 10 (37%) 3 (15.8%) 9 (20%) 
Arterial Hypertension 13 (48.1%)* 5 (26.3%) 8 (7.8%) 
Smoking 5 (18.5%) 2 (10.5%) 8 (7.8%) 
Diabetes  1 (3.7%) 0 6 (13.3%) 
LA 22 (81.5%) 16 (84.2%)  38 (84.4%) 
aCL IgG/M 18 (66.7%) 16 (84.2%)* 24 (53.3%) 
Anti-Beta2GPI IgG/IgM 15 (55.6%) 11 (57.9%) 15 (33.3%) 
Triple aPL positivity 7 (25.9%) 8 (42.1%) 9 (20%) 
aGAPSS (mean, SD) 10.4 ± 3.9* 10.6 ± 3.8* 8.16 ±3.15 
Table 2. Patients cardiovascular risk factors and aPL positivity between groups 
aPL= Antiphospholipid antibodies; S.D. = standard deviation; aGAPSS = adjusted global antiphospholipid 
score  
*statistically significantly different when compared with the group of “No extra -criteria manifestation” 
 
Patients with extra-criteria manifestations presented a mean aGAPSS 
of 10.30 (S.D. ±3.57, range 4-17), significantly higher when compared 
with patients without extra-criteria manifestations of APS (8.16; S.D. 
±3.52; range 4-16; p = 0.005). When comparing patients with and 
without extra-criteria manifestations, the first group had significantly 
higher incidence of anti-ß2GPI antibodies positivity (59% and 33%, 
respectively, p=0.015), double aPLpositivities (53% and 31%, 
respectively, p=0.034), cerebrovascular events history (52% and 24%, 
respectively, p=0.007) and arterial hypertension (52% and 24%, 
respectively, p=0.007).  
Similarly, when considering patients with livedo (both reticularis and 
racemosa), significantly higher aGAPSS values were seen when 
compared to patients with no extra-criteria manifestations [mean 
aGAPSS 10.4 (S.D. ±3.9, range 4-17) Vs. mean aGAPSS 8,16 (S.D. ±3.52; 
range 4-16;); p=0.014].Further statistically significant differences were 
seen in the livedo group when compared to the extra-criteria group 
when analyzing the rate of arterial events (74% and 47%, respectively, 
p=0.02), cerebrovascular events (70% and 24%, respectively, p<0.001) 
and arterial hypertension (44% and 71%, respectively, p=0.004). 
Interestingly, the livedo group had significantly lower rate of venous 
events (44% and 71%, respectively, p=0.025). When considering only 
patients with livedoreticularis, the same statistically significant 
differences were seen. However,  due to the small number of patients 
with livedoracemosa, a similar analysis could not be performed 
considering only the subgroup of patients with livedoracemosa.  
Likewise, when considering patients with thrombocytopenia, 
significantly higher aGAPSS values were seen when compared to 
patients with no extra-criteria manifestations [mean aGAPSS 10.6 (S.D. 
±3.8, range 4-17) p=0.018]. In patients with thrombocytopenia was 
also observed higher rate of aCL positivity (84% and 53%, 
respectively, p=0.02). 
Due to the small number of patients with biopsy proven APS 
nephropathy (aGAPSS range 8-14) and valvulopathy (aGAPSS range 9-
14), statistical differences could not be calculated separately for these 
manifestations. No statistical significant differences were observed 
when comparing separately each cardiovascular risk factor (smoking, 
diabetes, dyslipidemia) nor other thrombotic risk factor (hormonal 
therapy, immobilization, surgery, malignancy).  
4.1 Discussion:   
The GAPSS score was conceived and validated in a comprehensive 
series of studies evaluating different patients populations [5,16–18]. 
The GAPSS model evaluates the risk profile of patients to develop 
thrombosis or pregnancy morbidity in the context of aPL positivity, 
based on traditional cardiovascular risk factors and aPL profile, 
considered as independent risk factors for developing any clinical APS 
manifestation. Very recently, in a systematic review that included 2273 
patients, GAPSS was found to be a valid tool to stratify patients with 
aPL according to their thrombotic risk, being the highest levels of 
GAPSS found in patients who experienced thrombosis, especially 
arterial.  Furthermore, the GAPSS was also proven to identify patients 
at higher risk of developing recurrences of any clinical manifestations 
of APS[19].  
In the original GAPSS, anti-phosphatidylserine/prothrombin 
antibodies (aPS-PT) were included in the score. However, these are not 
currently part of the international consensus classification criteria [1] 
and aPS-PT antibodies are not routinely tested in most clinical 
laboratories. For the above reasons, in our current study we applied 
the aGAPSS (excluding aPS-PT), already tested and validated in 
previous studies [20–22].  
In this study, we highlight the clinical relevance of extra-criteria 
manifestations in risk assessment of APS using the aGAPSS. 
Our cohort included 89 thrombotic PAPS patients and 49% of those 
patients experienced at least one extra-criteria clinical manifestation of 
APS. Higher levels of aGAPSS were seen in patients with extra-criteria 
clinical manifestations of APS, both when analyzing the extra-criteria 
manifestations as a group or as single manifestations.  
Our results support the idea that patients with higher risk profile 
should undergo careful routine evaluation and risk assessment (Figure 
1).  
 
 This is particularly important for the risk of developing arterial events, 
that include the potentially most life-threatening manifestations of the 
syndrome, being the central nervous system the most common 
affected site [23] and that was found in this analysis highly associated 
with extra-criteria manifestations of APS.  
A throughout analysis of laboratory and instrumental investigation 
should be warranted in higher risk APS patients. aGAPSS might 
represents a substantial tool in identifying this particular subgroup 
and in quantifying the risk of developing any other clinical 
manifestation of APS, highly impacting on the clinical follow-up of 
patients and potentially in therapeutic long-term choices. Such patients 
may require intensified diagnostic workout during the follow-up (e.g 
routine echocardiography and routine microscopic examination of the 
urine sediment).  
Limitations of the study 
We acknowledge few limitations for our study.  
The use of a cross-sectional approach might influence the 
reproducibility of the results, as individual aGAPSS scores could variate 
at different time points. Further prospective analysis to confirm our 
findings is highly needed. However, one should consider the fact that 
APS is a rare condition and extra-criteria manifestations are present 
just in a subset of APS patients [4]. While a longitudinal study would be 
highly informative, a prospective data collection may require 
international joint efforts. From that perspective, it is worth 
mentioning the AntiPhospholipid syndrome alliance for clinical trials 
and International networking (APS ACTION) is the first-ever 
international research network that has been created specifically to 
design and conduct well-designed, large-scale, multicenter clinical 
studies in persistently aPL-positive patients [24–27]. 
Secondly, due to the retrospective nature of the data collection, the 
diagnosis of aPL-related nephropathy could only be assessed if the 
patient underwent a renal biopsy. Furthermore, extra-criteria 
neurological manifestations of APS are an heterogeneous group of 
clinical entities, sometimes very common in the general population 
(e.g. migraine, mood disorders), making their attribution to aPL might 
challenging.  
Finally, the effect of therapy and therapy compliance could not be 
properly assessed, as treatment was heterogeneously controlled in this 
cohort and varied according to the clinical manifestations and the 
clinician’s judgment. 
 
Conclusion 
To date, identifying APS patients who are at high risk for developing 
any thrombotic event is still an unmet clinical need and remains a 
major challenge for the treating physicians.  Following the findings of 
our study, we suggest that PAPS patients with a higher risk profile 
according to aGAPSS might be at higher risk for developing extra-
criteria manifestations (such as thrombocytopenia, livedo and/or 
nephropathy) and should therefore undergo a throughout laboratory 
and instrumental evaluation.  
With the help of joint efforts and multicenter prospective studies 
confirming our findings, aGAPSS might aid the treating clinician for 
risk stratification of APS patients.  
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